Lifecore Biomedical (NASDAQ:LFCR) Posts Earnings Results, Misses Estimates By $0.14 EPS

by · The Cerbat Gem

Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.14), FiscalAI reports. The company had revenue of $23.19 million during the quarter, compared to analysts’ expectations of $25.96 million. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 25.43%.

Here are the key takeaways from Lifecore Biomedical’s conference call:

  • Reaffirmed 2026 guidance and mid‑term targets — Lifecore reiterated 2026 revenue guidance of $120–125M and adjusted EBITDA of $20.5–25M, and reiterated a goal of 12% revenue CAGR and >25% EBITDA margin by end of 2029.
  • Q1 results disappointed — revenue fell 34% year‑over‑year to $23.2M, gross profit declined and the company reported a $15M net loss with adjusted EBITDA of $1M, driven by front‑loaded headwinds and timing shifts.
  • Notable business development wins — signed three commercial site‑transfer/CDMO agreements (including an aesthetics onshore transfer and two programs with a U.S. biopharma customer) and expanded a late‑stage pipeline, with these transfers expected to be commercial by 2028 and represent mid‑seven‑figure opportunities each.
  • Expense cuts and stronger liquidity — SG&A and R&D reduced by nearly $8M since late‑2024, fifth consecutive quarter of positive operating cash flow, and ending Q1 liquidity of ~ $38M (~$21M cash + ~$17M revolver availability).
  • Operational and quality progress — ERP implementation went smoothly in January, multiple customer inspections had positive outcomes, and the company is preparing to support a planned doubling of its largest customer’s commercial demand beginning in 2027.

Lifecore Biomedical Stock Down 0.6%

NASDAQ:LFCR traded down $0.03 on Friday, hitting $4.74. The stock had a trading volume of 116,346 shares, compared to its average volume of 268,107. The stock has a market cap of $177.66 million, a price-to-earnings ratio of -5.04 and a beta of 1.08. The business’s 50-day simple moving average is $5.19 and its two-hundred day simple moving average is $6.81. Lifecore Biomedical has a 52-week low of $3.63 and a 52-week high of $8.98.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Barrington Research boosted their price objective on Lifecore Biomedical from $5.50 to $6.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Weiss Ratings reissued a “sell (d)” rating on shares of Lifecore Biomedical in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $6.00.

Get Our Latest Report on Lifecore Biomedical

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC boosted its position in Lifecore Biomedical by 86.2% in the fourth quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock worth $2,059,000 after purchasing an additional 116,500 shares during the last quarter. AQR Capital Management LLC boosted its position in Lifecore Biomedical by 28.4% in the fourth quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock worth $132,000 after purchasing an additional 3,574 shares during the last quarter. Jump Financial LLC purchased a new position in Lifecore Biomedical in the fourth quarter worth about $123,000. Price T Rowe Associates Inc. MD boosted its position in Lifecore Biomedical by 20.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock worth $137,000 after purchasing an additional 2,826 shares during the last quarter. Finally, State of Wisconsin Investment Board lifted its position in shares of Lifecore Biomedical by 138.2% during the 4th quarter. State of Wisconsin Investment Board now owns 37,825 shares of the company’s stock valued at $309,000 after buying an additional 21,946 shares in the last quarter. 83.36% of the stock is owned by hedge funds and other institutional investors.

About Lifecore Biomedical

(Get Free Report)

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.

Featured Articles